You have a virus that doesn't just occupy hepatocytes; it converts them into viral factories and then invites the immune system to burn the whole factory down. To stop the progression to cirrhosis, you have to interrupt the viral assembly line before the structural remodeling becomes irreversible.
The central question: How does viral replication trigger the structural death of the liver?
01
How it works — the zoom from whole body to molecule
System to cell
1
System
the whole body at work
In a healthy state, hepatocytes are the metabolic powerhouses of the body, organized into functional lobules that process nutrients and detoxify the blood.
They are responsible for the massive synthetic output of albumin and clotting factors that maintain your oncotic pressure and your ability to stop bleeding.
The space of Disse remains clear, allowing for seamless exchange between the bloodstream and the cells.
This delicate balance is regulated by a steady flow of portal blood and biliary drainage.
2
Organ
the healthy sequence, step by step
Hepatocyte protein synthesis (Albumin/Clotting Factors)
Sinusoidal filtration of toxins
Biliary excretion of waste
Maintenance of low-pressure portal flow
3
Tissue & mechanism
where and why it breaks
The HCV life cycle is a high-speed assembly line that depends on specific viral proteins to replicate.
By understanding this line, you can see exactly where modern Direct-Acting Antivirals (DAAs) throw a wrench into the works.
The virus enters, uncoats, and then uses NS3/4A protease to snip its large polyprotein into functional pieces, NS5B to copy its RNA blueprint, and NS5A to organize the final assembly of new viral particles.
4
Cell & molecule
the break at its smallest scale
NS3/4A Protease cleavage of the viral polyprotein
NS5B RNA-dependent RNA polymerase replication of the genome
NS5A-mediated viral assembly and secretion
Triggering of the TGF-beta pathway in Stellate Cells
Progressive collagen cross-linking (remodeling the architecture)
5
The result
what the break produces
Viral RNA hijacking of the hepatocyte protein-synthesis machinery
Immune-mediated hepatocyte apoptosis
Activation of Hepatic Stellate Cells into myofibroblasts
Deposition of collagen in the Space of Disse (Fibrosis)
02
How it works when healthy
Normal anatomy & physiology
In a healthy state, hepatocytes are the metabolic powerhouses of the body, organized into functional lobules that process nutrients and detoxify the blood.
They are responsible for the massive synthetic output of albumin and clotting factors that maintain your oncotic pressure and your ability to stop bleeding.
The space of Disse remains clear, allowing for seamless exchange between the bloodstream and the cells.
This delicate balance is regulated by a steady flow of portal blood and biliary drainage.
The healthy sequence
1Hepatocyte protein synthesis (Albumin/Clotting Factors)
2Sinusoidal filtration of toxins
3Biliary excretion of waste
4Maintenance of low-pressure portal flow
03
Why it breaks
The mechanism
The HCV life cycle is a high-speed assembly line that depends on specific viral proteins to replicate.
By understanding this line, you can see exactly where modern Direct-Acting Antivirals (DAAs) throw a wrench into the works.
The virus enters, uncoats, and then uses NS3/4A protease to snip its large polyprotein into functional pieces, NS5B to copy its RNA blueprint, and NS5A to organize the final assembly of new viral particles.
Step by step
1NS3/4A Protease cleavage of the viral polyprotein
2NS5B RNA-dependent RNA polymerase replication of the genome
3NS5A-mediated viral assembly and secretion
4Triggering of the TGF-beta pathway in Stellate Cells
5Progressive collagen cross-linking (remodeling the architecture)
04
The failure chain
Pathophysiology of dysfunction
The shift starts when the Hepatitis C virus (HCV) enters the hepatocyte and uses the cell's own machinery to replicate its RNA.
This isn't just a quiet occupation; the presence of viral proteins triggers a chronic, smoldering immune response where CD8+ T-cells attack the infected hepatocytes.
This persistent 'friendly fire' leads to necroinflammation, which is the signal for the liver's repair crew—the stellate cells—to go into overdrive.
The first thing to break
Viral RNA hijacking of the hepatocyte protein-synthesis machinery
The cascade, in order
1Immune-mediated hepatocyte apoptosis
2Activation of Hepatic Stellate Cells into myofibroblasts
3Deposition of collagen in the Space of Disse (Fibrosis)
4Increased resistance to portal blood flow (Portal Hypertension)
05
Normal → Compensation → Decompensation → Failure
The full arc
1
Compensated
What you see
Normal Albumin/INR
No physical signs (asymptomatic)
Slightly elevated LFTs
What fools you
The patient feels totally fine and their labs might look 'boring,' but the stellate cells are silently building a wall of collagen.
2
Decompensated
What you see
Jaundice
Ascites
Scleral icterus
3
Failure
What you see
Encephalopathy
Variceal Bleeding
Hepatorenal Syndrome
What dies
The portal pressure is too high and the liver can't clear toxins (ammonia), leading to systemic collapse and multi-organ failure.
06
Tied to the mechanism
Why the symptoms appear
The chain that produces them
1Immune-mediated hepatocyte apoptosis
2Activation of Hepatic Stellate Cells into myofibroblasts
3Deposition of collagen in the Space of Disse (Fibrosis)
4Increased resistance to portal blood flow (Portal Hypertension)
What surfaces at each stage
Compensated
Normal Albumin/INR
No physical signs (asymptomatic)
Slightly elevated LFTs
Decompensated
Jaundice
Ascites
Scleral icterus
Failure
Encephalopathy
Variceal Bleeding
Hepatorenal Syndrome
07
Each drug → the exact broken step it fixes
What the medications do
NS3/4A Protease Inhibitors (e.g., Glecaprevir)
interrupts: Viral polyprotein processing
These act as the 'scissors-guard,' preventing the virus from cutting its long protein chain into the functional tools it needs to survive.
Without these cuts, the virus is essentially born with its hands tied.
Do not use these in patients with Child-Pugh B or C because the drug levels can become toxic as liver function fails.
NS5A Inhibitors (e.g., Velpatasvir)
interrupts: Viral assembly and secretion
This interrupts the 'foreman' of the viral factory, stopping the virus from organizing its RNA and proteins into a shippable package.
It breaks the assembly line at the final stage.
These are the backbone of pangenotypic regimens because they are highly potent against most HCV variants.
NS5B Polymerase Inhibitors (e.g., Sofosbuvir)
interrupts: RNA replication
This is a chain-terminator that mimics the building blocks of RNA; the virus tries to use it to copy its genome, but it hits a dead end.
It effectively jams the copying machine.
It is a 'nucleotide analog' and is the cornerstone of most modern curative 'one-pill' regimens.
Ribavirin
interrupts: Viral RNA synthesis and mutagenesis
An older-school move that creates so many mutations in the viral genome that the virus essentially 'mutates to death.' We use this now only in the toughest cases—usually when previous DAA therapy has failed or in complex cirrhosis cases.
Watch for hemolytic anemia; it's a known side effect that can tank your patient's H&H.
HAV/HBV Vaccinations
interrupts: Synergistic hepatocyte damage
This isn't for HCV itself, but to prevent 'second hits' to an already stressed liver.
Getting a second viral hepatitis on top of HCV is the fast track to liver failure.
Every clinician should ensure their HCV patient is immune to the other 'letters' in the hepatitis alphabet.
08
Confirm it, track it, act on it
Labs & outcomes
Serologies identify the virus + confirm acuity.
Hepatitis serologies (HAV IgM, HBsAg + IgM anti-HBc, anti-HCV, HCV RNA, HEV)Specific patterns for each
Identifies virus
LFTs (AST, ALT, alk phos, bilirubin)ALT often >1000 in acute
Hepatocellular pattern severity
INR + albuminMarkers of severity
Synthetic function
CBC + BMPStandard workup
Anemia, AKI
HIV testingAlters management
Co-infection (especially HCV)
Acetaminophen levelMajor reversible mimic
Concurrent toxicity
Interventions
Supportive care (rest, hydration, avoid hepatotoxins)All acute viral hepatitis
Foundation
Antivirals for severe acute HBV (entecavir, tenofovir)Severe acute or fulminant HBV
Reduces chronicity risk
Direct-acting antivirals for acute HCVWithin 6 months
Long-term monitoring for chronicity (HBV, HCV)All HBV/HCV
30-50% become chronic
What this means at the bedside
Anticipate: Screen every adult at least once (per CDC guidelines) because curative treatment prevents the transition from 'viral factory' to 'cirrhotic rock.'
Watch for: A sudden drop in platelets or a new-onset umbilical hernia, which signals the shift from compensated to portal hypertension.
Uncertainty: While DAAs offer a 95%+ cure rate, the long-term regression of advanced fibrosis after cure is still a variable, patient-specific process.
We'd like to log de-identified learning events (module viewed, time on section, quiz correct/incorrect) to improve the platform. No personal data, no patient identifiers, no external browsing.
We use a small set of cookies to keep you signed in and to remember your track. Optional, anonymous analytics help us find broken pages. Read more.
Install Maldek CHIN as an app — studies work even offline